Fight for the survival of more patients with locally advanced thyroid cancer

Professor Wang Yu, Director of Head and Neck Surgery, Fudan University Cancer Hospital, led the team to innovate and explore the use of the targeted drug anlotinib for neoadjuvant therapy for locally advanced thyroid cancer, so as to win the opportunity
for advanced patients to operate.

This result is the first in the world to successfully prove the effectiveness of anlotinib in neoadjuvant therapy for thyroid cancer, and Professor Yu Wang's team published the research results of neoadjuvant therapy for thyroid cancer online in Thyroid, an authoritative journal in the field of thyroid diseases, filling the gap
in the treatment of locally advanced thyroid cancer.

Professor Wang Yu said: "Multidisciplinary comprehensive treatment based on surgery is the main method for the radical treatment of thyroid cancer, which can obtain very good results
.
He told reporters: "But not all thyroid cancer patients are lucky, and some locally advanced thyroid cancer patients who have lost the opportunity for radical surgery are not optimistic
due to the lack of treatment countermeasures.
" ”

In order to give more patients with locally advanced thyroid cancer the opportunity to completely remove their tumors by surgery, Professor Wang Yu led the team to carry out a clinical study
on the neoadjuvant treatment of the targeted drug anlotinib in locally advanced thyroid cancer.
Nearly seventy percent of the patients with locally advanced thyroid cancer included in the study who could not be directly radically cured achieved the desired results and eventually successfully underwent radical resection
.
"This result is the first in the world to successfully prove the effectiveness of anlotinib in neoadjuvant therapy for thyroid cancer, and has won the opportunity for advanced patients to operate; More importantly, the neoadjuvant treatment model is expected to become a new option
for the treatment of locally advanced thyroid cancer.
Professor Wang Yu said
.

It is reported that as one of the well-known thyroid cancer diagnosis and treatment centers in China, the annual outpatient volume of head and neck surgery in Fudan University Cancer Hospital exceeds 110,000, and the 5-year survival rate of thyroid cancer patients is 98.
35%, which is comparable
to the current level of international top thyroid cancer centers.